计算溶液所需的质量、体积或浓度。
Guselkumab (anti-IL-23) (Ab175717) - SEC
The purity of Guselkumab (anti-IL-23) (Ab175717) is more than 95% verified by HPLC.
| 货号 (SKU) | 包装规格 | 是否现货 | 价格 | 数量 |
|---|---|---|---|---|
| Ab175717-100μg |
100μg |
现货 ![]() |
| |
| Ab175717-1mg |
1mg |
现货 ![]() |
| |
| Ab175717-5mg |
5mg |
现货 ![]() |
| |
| Ab175717-10mg |
10mg |
期货 ![]() |
|
| 产品名称 | Guselkumab (anti-IL-23), 白细胞介素 23 抑制剂 |
|---|---|
| 别名 | 古塞库单抗 | 古塞库单抗(抗 IL-23) |
| 英文别名 | IL 23 A antibody | IL 23 antibody | IL 23 subunit alpha antibody | IL 23A antibody | IL 23p19 antibody | IL-23 subunit alpha antibody | IL-23-A antibody | IL-23p19 antibody | IL12B antibody | IL23 antibody | Il23a antibody | IL23A_HUMAN antibody | IL23P19 |
| 规格或纯度 | 无载体, 重组, ExactAb™, 低内毒素, 无叠氮钠, 已验证, 无动物源, ≥95%(SDS-PAGE&SEC-HPLC), 见COA |
| 宿主种属 | 人(Human) |
| 特异性 | IL23A |
| 种属反应性 | 人(Human),食蟹猴(Cynomolgus monkey) |
| 偶联 | Unconjugated |
| 作用类型 | 抑制剂 |
| 作用机制 | 白细胞介素 23 抑制剂 |
| 克隆类型 | 重组抗体 |
|---|---|
| Format | Whole IgG |
| 亚型 | Human IgG1 |
| 轻链亚型 | lambdaC2 |
| SDS-PAGE | 27.8 kDa (Light Chain) & 50.7 kDa (Heavy Chain), under reducing conditions; 170.7 kDa, under non-reducing conditions. |
| 纯化方法 | Protein A purified |
| 纯度 | >95% |
| 物理外观 | Liquid |
| 储存缓冲液 | Supplied as a 0.22 μm filtered solution in 100mM Pro-Ac, 20mM Arg, pH 5.0 |
| 防腐剂 | No |
| 浓度 | 见COA |
| 储存温度 | -80℃储存,避免反复冻融 |
| 运输条件 | 超低温冰袋运输 |
| 稳定性与储存 | 在 -80℃ 下保存 24 个月。收货后建议分装。避免冷冻/解冻循环。 |
| CAS编号和信息 | 1350289-85-8 |
| 分子类型 | 抗体 |
Guselkumab (anti-IL-23) (Ab175717) - SEC
The purity of Guselkumab (anti-IL-23) (Ab175717) is more than 95% verified by HPLC.
Guselkumab (anti-IL-23) (Ab175717) - ELISA
Immobilized IL-23 at 2 μg/mL can bind Guselkumab (anti-IL-23) (Ab175717) with the EC₅₀ of 16.45 ng/mL.
通过匹配包装上的批号来查找并下载产品的 COA,每批产品都进行了严格的验证,您可放心使用!
| 批号(Lot Number) | 证书类型 | 日期 | 货号 |
|---|---|---|---|
| 分析证书 | 24-12-04 | Ab175717 | |
| 分析证书 | 24-12-04 | Ab175717 | |
| 分析证书 | 24-12-04 | Ab175717 | |
| 分析证书 | 23-12-13 | Ab175717 | |
| 分析证书 | 23-12-13 | Ab175717 |
¥1,219.90
¥559.90
¥559.90
¥769.90
| 1. Parham C, Chirica M, Timans J, Vaisberg E, Travis M, Cheung J, Pflanz S, Zhang R, Singh KP, Vega F et al.. (2002) A receptor for the heterodimeric cytokine IL-23 is composed of IL-12Rbeta1 and a novel cytokine receptor subunit, IL-23R.. J Immunol, 168 (11): (5699-708). [PMID:12023369] |
| 2. Campa M, Mansouri B, Warren R, Menter A. (2016) A Review of Biologic Therapies Targeting IL-23 and IL-17 for Use in Moderate-to-Severe Plaque Psoriasis.. Dermatol Ther (Heidelb), 6 (1): (1-12). [PMID:26714681] |
| 3. Oppmann, B B and 24 more authors.. (2000) Novel p19 protein engages IL-12p40 to form a cytokine, IL-23, with biological activities similar as well as distinct from IL-12.. Immunity, [PMID:11114383] |
| 4. Pirhonen, Jaana J, Matikainen, Sampsa S and Julkunen, Ilkka I.. (2002) Regulation of virus-induced IL-12 and IL-23 expression in human macrophages.. Journal of immunology (Baltimore, Md. : 1950), (15): [PMID:12421946] |
| 5. Smits, Hermelijn H HH and 8 more authors.. (2004) Commensal Gram-negative bacteria prime human dendritic cells for enhanced IL-23 and IL-27 expression and enhanced Th1 development.. European journal of immunology, [PMID:15114670] |
| 6. Schnurr, Max M and 5 more authors.. (2005) Extracellular nucleotide signaling by P2 receptors inhibits IL-12 and enhances IL-23 expression in human dendritic cells: a novel role for the cAMP pathway.. Blood, (15): [PMID:15486065] |
| 7. Fedele, Giorgio G and 5 more authors.. (2005) Bordetella pertussis-infected human monocyte-derived dendritic cells undergo maturation and induce Th1 polarization and interleukin-23 expression.. Infection and immunity, [PMID:15731058] |
| 8. Vanden Eijnden, Serge S, Goriely, Stanislas S, De Wit, Dominique D, Goldman, Michel M and Willems, Fabienne F.. (2006) Preferential production of the IL-12(p40)/IL-23(p19) heterodimer by dendritic cells from human newborns.. European journal of immunology, [PMID:16342235] |
| 9. Piskin, Gamze G, Sylva-Steenland, Regien M R RM, Bos, Jan D JD and Teunissen, Marcel B M MB.. (2006) In vitro and in situ expression of IL-23 by keratinocytes in healthy skin and psoriasis lesions: enhanced expression in psoriatic skin.. Journal of immunology (Baltimore, Md. : 1950), (1): [PMID:16424222] |
| 10. Langowski, John L JL and 9 more authors.. (2006) IL-23 promotes tumour incidence and growth.. Nature, (27): [PMID:16688182] |
| 11. Vaknin-Dembinsky, Adi A, Balashov, Konstantin K and Weiner, Howard L HL.. (2006) IL-23 is increased in dendritic cells in multiple sclerosis and down-regulation of IL-23 by antisense oligos increases dendritic cell IL-10 production.. Journal of immunology (Baltimore, Md. : 1950), (15): [PMID:16751425] |
| 12. Wilson, Nicholas J NJ and 15 more authors.. (2007) Development, cytokine profile and function of human interleukin 17-producing helper T cells.. Nature immunology, [PMID:17676044] |
| 13. Lupardus, Patrick J PJ and Garcia, K Christopher KC.. (2008) The structure of interleukin-23 reveals the molecular basis of p40 subunit sharing with interleukin-12.. Journal of molecular biology, (17): [PMID:18680750] |
| 14. Papp, K K and 12 more authors.. (2015) Tildrakizumab (MK-3222), an anti-interleukin-23p19 monoclonal antibody, improves psoriasis in a phase IIb randomized placebo-controlled trial.. The British journal of dermatology, [PMID:26042589] |
| 15. Bloch, Yehudi and 11 more authors.. (2018) Structural Activation of Pro-inflammatory Human Cytokine IL-23 by Cognate IL-23 Receptor Enables Recruitment of the Shared Receptor IL-12Rβ1.. Immunity, (16): [PMID:29287995] |
| 16. Haugh, Isabel M; Preston, Allie K; Kivelevitch, Dario N and Menter, Alan M.. (2018) Risankizumab: an anti-IL-23 antibody for the treatment of psoriasis.. Drug design, development and therapy, [PMID:30518998] |
| 17. Machado, Álvaro Á and Torres, Tiago T.. (2018) Spotlight on risankizumab and its potential in the treatment of plaque psoriasis: evidence to date.. Psoriasis (Auckland, N.Z.), [PMID:30519540] |
| 18. Sun, Rui and Abraham, Clara.. (2020) IL23 Promotes Antimicrobial Pathways in Human Macrophages, Which Are Reduced With the IBD-Protective IL23R R381Q Variant.. Cellular and molecular gastroenterology and hepatology, [PMID:32474165] |
| 19. Glassman, Caleb R and 10 more authors.. (2021) Structural basis for IL-12 and IL-23 receptor sharing reveals a gateway for shaping actions on T versus NK cells.. Cell, (18): [PMID:33606986] |